Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:577-603. doi: 10.1146/annurev-pharmtox-010818-021154. Epub 2018 Oct 8.

Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?

Author information

1
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA; email: minoli.perera@northwestern.edu.

Abstract

Race and ancestry have long been associated with differential risk and outcomes to disease as well as responses to medications. These differences in drug response are multifactorial with some portion associated with genomic variation. The field of pharmacogenomics aims to predict drug response in patients prior to medication administration and to uncover the biological underpinnings of drug response. The field of human genetics has long recognized that genetic variation differs in frequency between ancestral populations, with some single nucleotide polymorphisms found solely in one population. Thus far, most pharmacogenomic studies have focused on individuals of European and East Asian ancestry, resulting in a substantial disparity in the clinical utility of genetic prediction for drug response in US minority populations. In this review, we discuss the genetic factors that underlie variability to drug response and known pharmacogenomic associations and how these differ between populations, with an emphasis on the current knowledge in cardiovascular pharmacogenomics.

KEYWORDS:

cardiovascular; genetic variation; minority populations; pharmacogenomics; polymorphism

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center